Actively Recruiting

Phase 1
Age: 19Years - 60Years
MALE
Healthy Volunteers
NCT07407543

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SRN001 in Healthy Korean and Caucasian Adult Males

Led by siRNAgen Therapeutics Inc. · Updated on 2026-02-12

30

Participants Needed

1

Research Sites

68 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of SRN001 in healthy adult volunteers.

CONDITIONS

Official Title

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SRN001 in Healthy Korean and Caucasian Adult Males

Who Can Participate

Age: 19Years - 60Years
MALE
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Healthy Korean or Caucasian male volunteers aged 19 to 60 years at screening
  • Weigh 50 kg or more with a body mass index between 18.5 and 29.9 kg/m2
  • Serum amphiregulin concentration of 100 pg/mL or higher at screening
  • Voluntarily agree to participate and provide written informed consent
Not Eligible

You will not qualify if you...

  • History or presence of significant diseases affecting liver, kidney, nervous, immune, respiratory, digestive, endocrine, blood, heart, urinary, psychiatric systems, or sexual dysfunction
  • History of hypersensitivity to RNA drugs or other drugs, or significant allergic reactions
  • Positive tests for hepatitis B, hepatitis C, HIV, or syphilis
  • History of drug abuse or positive urine drug screen
  • Abnormal vital signs including low or high blood pressure, pulse rate, or body temperature
  • Abnormal electrocardiogram findings such as QTcF greater than 450 msec
  • Elevated liver enzymes or reduced kidney function based on lab tests
  • Recent use of prescription, over-the-counter drugs, herbal medicines, or supplements within 1-2 weeks before dosing
  • Use of enzyme inducers or inhibitors like barbiturates or clarithromycin within one month before dosing
  • Participation in another clinical trial or receipt of investigational drug within 6 months
  • Recent blood donation or transfusion
  • Current smokers or unable to quit smoking before and during the trial
  • Regular alcohol consumption exceeding limits or inability to abstain before and during the trial
  • Excessive caffeine intake or inability to abstain before and during the trial
  • Consumption of grapefruit or grapefruit-containing foods before and during the trial
  • Unusual eating habits or inability to follow standardized diet during hospitalization
  • Use of own condoms during the trial or partners not using effective contraception
  • Refusal to abstain from sperm donation during the trial
  • Any other condition deemed unsuitable by the investigator for trial participation

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Seoul National University Hospital

Seoul, South Korea

Actively Recruiting

Loading map...

Research Team

E

Eunkyeong Woo

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

SEQUENTIAL

Primary Purpose

TREATMENT

Number of Arms

4

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SRN001 in Healthy Korean and Caucasian Adult Males | DecenTrialz